Drugs Made In America Acquisition (DMAA) Cash from Financing Activities (2025)

Drugs Made In America Acquisition (DMAA) reported Cash from Financing Activities of $130600.0 for Q4 2025, up 133.2% quarter-over-quarter from $56003.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Cash from Financing Activities (2025) Analysis & Trends

Drugs Made In America Acquisition has reported Cash from Financing Activities for 1 years, with the latest figure at $130600.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities changed N/A year-over-year to $130600.0; the trailing twelve-month figure through Dec 2025 stood at $231.7 million (changed N/A YoY), and the FY2025 full-year result was $231.7 million, up 133351.97% from the prior year.
  • Cash from Financing Activities for Q4 2025 stood at $130600.0, up from $56003.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $231.4 million in Q1 2025, with the low at $56003.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -
2 Berto Acquisition 312.46 Mn 312.46 Mn - -250,000.00
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - -43,625.00
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - 500,000.00
6 WEN Acquisition 309.15 Mn 309.15 Mn - -13,092.00
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - -
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 1.27 Mn
9 BTC Development 262.16 Mn 262.16 Mn - -
10 Drugs Made In America Acquisition 223.11 Mn 223.11 Mn - 130,600.00

Historic Data

Download Data
DateValue
Dec 31, 2025 130,600.00
Dec 31, 2025 130,600.00
Sep 30, 2025 56,003.00
Sep 30, 2025 56,003.00
Jun 30, 2025 106,554.00
Jun 30, 2025 106,554.00
Mar 31, 2025 231.40 Mn
Mar 31, 2025 231.40 Mn